Last updated on December 2019

Phase 3 Study of Cx601 in Subjects With Complex Perianal Fistulising Crohn's Disease

Brief description of study

The purpose of this study is to evaluate the efficacy of Darvadstrocel for the treatment of complex perianal fistulas in adult patients with Crohn's disease over 24 weeks.

Detailed Study Description

The product being tested in this study is called Darvadstrocel (Cx601). This study will assess the efficacy for 24 and 52 weeks, and safety for 156 weeks of Darvadstrocel when administered with intralesional injection in adult patients with Crohn's disease whose complex perianal fistulas were previously treated and refractory.

The study will enroll 20 participants. All participants who will meet the criteria will be assigned to screening period for approximately 5 weeks and after that will be enrolled the treatment period which will be the day of study product administration. After the treatment period, this study will include the follow-up period for approximately 52 weeks after study product administration, and the long-term follow-up period from Week 52 to Week 156.

This multi-center trial will be conducted in Japan. The overall time to participate is totally approximately 156 weeks (3 years) from the start of treatment period plus follow-up and long-term follow-up period. Participants will make multiple visits to the clinic and a final visit 156 weeks after treatment of study product for a follow-up assessment.

Clinical Study Identifier: NCT03706456

Find a site near you

Start Over

Ieda Hospital

Toyota, Japan
  Connect »